Is VIVO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

319 people get VIVO articles and Market Currents by email alert.

Get email alerts on VIVO »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Meridian Bioscience: An Overvalued Dividend Contender
Analytical Chemist • Tue, Apr 12, 2011 • 7 Comments
Meridian Bioscience Inc. Dividend Stock Analysis
Dividends4Life • Mon, Mar 15, 2010
Meridian: A Timely Stock to Consider
Robert Freedland • Mon, Nov 9, 2009
Meridian Biosciences: A Strong Long Term Investment
New Low Observer • Fri, Mar 27, 2009 • 1 Comment
Meridian Bioscience Offers Immunization from Recession
J Clinton Hill • Thu, Dec 11, 2008 • 4 Comments
Meridian Bioscience Update
Robert Freedland • Tue, Jul 22, 2008
Why I'm Taking a Chance on Meridian
Robert Freedland • Fri, Jul 18, 2008 • 4 Comments
The Long Case on Meridian Bioscience
Robert Freedland • Mon, Apr 14, 2008 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

10 Hot Healthcare Dogs Probe 6% To 38.2% Gains In April
Fredrik Arnold • Mon, May 13 • 2 Comments
9 Top Healthcare Dogs Hunt 3.5% To 51.9% Gains In April
Fredrik Arnold • Mon, May 6
Money Managers Are Buying 5 Dividend Stocks With A Higher ROI Than Industry Peers
Kapitall • Wed, Apr 17
Money Managers Are Buying These 5 Dividend Stocks With Higher ROI Than Industry Peers
Kapitall • Fri, Mar 8 • 1 Comment
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
5 Dividend Stocks Yielding Above 3% In Uptrend
Arie Goren • Thu, Nov 22, 2012 • 5 Comments
Profiting From The Trend Towards Point Of Care Diagnostics
Paul Nouri • Tue, Nov 20, 2012 • 13 Comments
3 Companies To Consider In The Wake Of Yet Another Red Flag For Dendreon
Matt Schilling • Mon, Oct 15, 2012 • 21 Comments
2 Biotech Companies Investors Should Watch As Analysts Initiate Buy Ratings
Matt Schilling • Sun, Oct 14, 2012 • 2 Comments
The Best Income Stocks You've Never Heard Of
StreetAuthority • Wed, Aug 29, 2012 • 2 Comments
3 Highly Liquid Dividend Stocks Holding Down The Debt
ZetaKap • Wed, Aug 29, 2012 • 2 Comments
7 Profitable Small-Cap Healthcare Stocks With Cash On Hand
ZetaKap • Thu, Aug 2, 2012 • 1 Comment
7 Small Cap Healthcare Stocks Bringing In Cash And Maintaining Great Liquidity
ZetaKap • Mon, Jul 30, 2012
Update: 8 High-Growth Healthcare Stocks With Strong Sources Of Profitability
Kapitall • Tue, Jul 17, 2012
3 Outperforming Stocks Releasing Earnings Next Week With Impressive Profitability
Kapitall • Wed, Jul 11, 2012
2 High-Yield Dividend Stocks To Avoid
Marc Lichtenfeld • Thu, May 3, 2012 • 3 Comments
Cepheid Punished For Unwelcome Variability
Stephen Simpson • Fri, Apr 20, 2012 • 2 Comments
5 Stocks That Could Be Bought Out In 2012
Stock Croc • Sun, Feb 12, 2012 • 2 Comments
Finding High-Yield Stocks With Major Growth Prospects
MyPlanIQ • Tue, Feb 7, 2012
The Dividend Achievers Of 2012
Dividends4Life • Tue, Feb 7, 2012 • 13 Comments

There are no Transcripts on VIVO.

Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Business Wire (Apr 25, 2013)
Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies

Business Wire (Mar 28, 2013)
Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA

Business Wire (Mar 18, 2013)
Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation

Business Wire (Feb 6, 2013)
Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance

Business Wire (Jan 23, 2013)
Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests

Business Wire (Dec 13, 2012)
Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012

Business Wire (Dec 4, 2012)
Midday Movers: AEO, ANN, KCG & More

at CNBC.com (Nov 28, 2012)
SensiFAST™ Genotyping Kit Exceed the Limit

Business Wire (Nov 28, 2012)
Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Business Wire (Nov 8, 2012)
Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group A Strep

Business Wire (Sep 17, 2012)
Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2013 and Reaffirms Fiscal 2012 Guidance

Business Wire (Aug 28, 2012)
Health Care Sector Wrap

at Fox Business (Aug 14, 2012)
Health Care Sector Wrap

at Fox Business (Aug 14, 2012)
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2012 Guidance

Business Wire (Jul 26, 2012)
Meridian Bioscience, Inc. to Release Fiscal 2012 Third Quarter and Nine Months Operating Results on July 26

Business Wire (Jul 17, 2012)
Meridian Bioscience Reports Record Second Quarter and First Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance

Business Wire (Apr 26, 2012)
Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C. difficile and Group B Streptococcus

Business Wire (Apr 12, 2012)
Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26

Business Wire (Apr 12, 2012)
Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene® Group B Streptococcus

Business Wire (Mar 21, 2012)

VIVO vs. ETF Alternatives

Company Description

Meridian is a fully-integrated life science company whose principal businesses are (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain respiratory, gastrointestinal, viral and parasitic infectious diseases, (ii) the manufacture and distribution... More

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, April 25, 1:57 PM Meridian Bioscience, Inc. (VIVO) declares $0.19/share quarterly dividend, in line with previous. Forward yield 3.61%. For shareholders of record May 04. Payable May 14. Ex-div date May 01. (PR) Comment! [Dividends]
Thursday, April 25, 11:35 AM Meridian Bioscience (VIVO): Q1 EPS of $0.24 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 11:19 AM Meridian Biosciences (VIVO -5%) slides after reporting a mixed FQ2 this morning, with its EPS coming in at $0.24, in line with the Street, but revenue came in at $47.3M versus the estimated $49.66M. Sales were flat year over year. USDx sales increased by 7%, driven primarily by increases in C. difficile and foodborne test revenues. EURDx business unit sales -12%, due largely to continued weakness in European healthcare spending. Meridian Life Science revenue -8%. Comment! [Healthcare, Earnings, On the Move]
Wednesday, January 23, 7:36 AM Meridian Bioscience (VIVO): FQ1 EPS of $0.2 beats by $0.01. Revenue of $45.4M beats by $. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, December 13, 2012, 4:05 PM Meridian Bioscience (VIVO -1.4%) says it's successfully completed beta trials for two new illumigene molecular amplification tests. The assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae from both swab and urine samples. Comment! [Healthcare, On the Move]
Tuesday, December 4, 2012, 10:23 AM Meridian Bioscience (VIVO) declares $0.19/share quarterly dividend, in line with previous. Forward yield 3.80%. For shareholders of record Dec. 14. Payable Dec. 24. Ex-div date Dec. 12. (PR) Comment! [Dividends]
Thursday, November 8, 2012, 9:43 AM Meridian Bioscience, Inc. (VIVO) declares $0.19/share quarterly dividend, in line with previous. For shareholders of record Nov. 19. Payable Nov. 30. Ex-div Nov. 15. (PR) Comment! [Dividends]
Thursday, November 8, 2012, 8:23 AM Meridian Bioscience (VIVO): Q3 EPS of $0.21 misses by $0.01. Revenue of $43.7M (+5.7% Y/Y) misses by $3M. (PR) Comment! [Earnings, Healthcare]
Thursday, July 26, 2012, 10:55 AM Meridian Bioscience (VIVO): FQ3 EPS of $0.21 misses by $0.01. Revenue of $42.1M (+5% Y/Y) misses by $4.4M. (PR) Comment! [Earnings, Healthcare]
Thursday, April 26, 2012, 10:51 AM Meridian Bioscience (VIVO): FQ2 EPS of $0.23 beats by $0.02. Revenue of $47.4M (+15.3% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
Wednesday, January 25, 2012, 5:40 PM Meridian Bioscience (VIVO -6.4%) had a rough day after reporting FQ1 revenue of $40.3M (+8% Y/Y) and EPS of $0.17, missing consensus by $3M and $0.02. The company notes its European diagnostic equipment business "continues to be a drag" on its performance, and that restructuring efforts "will take several more quarters to make a measurable difference." Comment! [Healthcare, Earnings, On the Move]
Tuesday, December 27, 2011, 11:56 AM Meridian Bioscience (VIVO -0.4%) receives FDA clearance for a molecular diagnostics test for group B streptococcus. The firm says the new test will allow quicker identification of infections. Comment! [Healthcare]
Thursday, November 10, 2011, 3:37 PM Meridian Bioscience (VIVO +2.6%) trades up despite its FQ4 earnings falling slightly short of analysts' estimates. Revenue rose a solid 16% Y/Y on an increase in European and global sales. The company also reaffirms FY12 guidance at the low end of its range, but in line with the Street's consensus view. Comment! [Healthcare, On the Move]
Thursday, July 21, 2011, 9:45 AM More on Meridian Bioscience (VIVO -12%): Despite a double-digit increase in sales, margins fell on continued weakness from its European diagnostics and core life science units. On a local currency basis, European diagnostics revenue fell 6%, while core life science declined 12%. Comment! [Healthcare, On the Move]
Thursday, July 21, 2011, 9:16 AM Meridian Bioscience (VIVO): Q3 EPS of $0.17 misses by $0.04. Sales of $40.1M (+18% Y/Y) misses by $3M. Revises down its fiscal 2011 guidance. (PR). Shares -12.5% premarket. Comment! [Healthcare, On the Move]
Thursday, July 7, 2011, 3:21 PM Meridian Bioscience (VIVO +3.6%) gains on a Lazard upgrade. The firm cites improved FY12 sales visibility on its test menu for illumigene C. difficile - an infection that causes diarrhea - plus an expansion of the menu to include tests for Group B strep. Comment! [Healthcare, On the Move]

ltfinger
Potential Upgrades (5/3/13): $RCII, $RS, $SNDK, $SPW, $TEVA, $TEX, $TKR, $VIVO, $VMW, $WLL, $ZBRA
May 6, 9:40 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kapitall
Money managers are buying 5 dividend stocks with a higher ROI than industry peers $NRCI $AFL $NUS $RMD $VIVO http://seekingalpha.com/a/svc5
Apr 17, 8:27 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Highly Liquid Dividend Stocks Holding Down The Debt http://bit.ly/Ou7Ud6 $CWCO $PETS $VIVO @ZetaKap
8/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Profitable Small-Cap Healthcare Stocks With Cash On Hand http://bit.ly/OrPoFo $AMSG $ATRI $HITK $KH $SCLN $VIVO $VPHM @ZetaKap
8/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alan Brochstein
Will $LMNX (reports 7/30) end up like $CPHD or $VIVO? Hope not!
7/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
Closed shorts $VMC $PRGS and longs $TRQ $VIVO for avg 5 day market neutral return of 2.1%! get today's trades on http://bit.ly/vVGjCq
2/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
The Best Healthcare Dividend Stocks With Fastest Earnings Growth + http://bit.ly/z4QIpy + $GSK $VIVO $NVS $RDSMY.PK $PETS $ABT $JNJ $LNCR
2/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
12 Healthcare Dividend Stocks With Best Future EPS Growth: http://bit.ly/rWJIWC + $VIVO $LNCR $MSA $WST $PPDI $USPH $LMAT $RELV $MR $RDY
12/2/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
20 Dividend Achiever With Highest Earnings Forecasts: http://bit.ly/sIz4JM + $PBCT $VIVO $NUE $MSA $SWK $GGG $CAT $WST $TDS $TNC $AOS $PII
11/29/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Good moves into the close for $VIVO $AMCC and $NR. Good volume in AMCC, the rest could have used more $$
11/15/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Michael Kudrna
Italy Has Finally Entered Our Markets (w/ Economic Calendar & Stock Radar) $DEJ $GST $AMCC $SPY $IWM $NR $VIVO http://bit.ly/sekgok/
11/14/11
Reply (6)

• !Report Abuse
View all 6 replies
psmith819: well i guess it was more hype than anything - just thought they made more progress in certain areas.
11/14/11
• !Report Abuse
Michael Kudrna: Im happy with the progress...sure I want more, but the fact they dont need to dilute speaks very highly of what they've done so far
11/14/11
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
A Strong Season For Trading (w/ Economic Calendar, Stock Radar & Jobs Report) $SPY $IWM $TRGT $VIVO $CSIQ $$ http://bit.ly/vIYOp6/
11/6/11
Reply (2)

• !Report Abuse
View all 2 replies
topsi: Hi Michael I have been holding BORN for a long time with quite a loss.what's your opinion?Iris ishawdesign@hotmail.com
11/7/11
• !Report Abuse
Michael Kudrna: Topsi, I sent you a reply on SeekingAlpha email system. Hope it helps.
11/7/11
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Initiated small position back in $VIVO about 17.55. Watching before making it a bigger bet
11/2/11
Reply (4)

• !Report Abuse
View all 4 replies
Michael Kudrna: Glad it helps....just remember that it will stop at some point, so always be mindful of that
11/2/11
• !Report Abuse
Michael Kudrna: Glad it helps....just remember that it will stop at some point, so always be mindful of that
11/2/11
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Initiated a small swing trade in $VIVO at 16.75 after large block purchase this morning, tight stops while I do more homework $$
10/25/11
Reply (2)

• !Report Abuse
View all 2 replies
cheme: What are your findings? Heavy volume today.
10/25/11
• !Report Abuse
Michael Kudrna: Nothing yet, I need to dig deeper, that's why my position is small
10/25/11
• !Report Abuse
Add a reply...

140 characters

VIVO Meridian Bioscience Inc.

VIVO

Meridian Bioscience Inc.